Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New blood pressure medication has fewer side effects: global study

02.04.2008
Telmisartan is as effective as ramipril in reducing cardiovascular death
Hamilton, ON (March 31, 2008) – A major Canadian-led global study has found that a new blood pressure medication is effective in reducing cardiovascular death, with fewer side effects than the current standard of care.

The study found a new drug telmisartan is as effective as the popular drug ramipril in reducing cardiovascular death in high risk patients and it has fewer side effects.

Dr. Salim Yusuf, director of the Population Health Research Institute at McMaster University and Hamilton Health Sciences and principal investigator of the study, presented the results of ONTARGET today at the American College of Cardiology conference. The paper has also been published on-line by the New England Journal of Medicine.

Previous studies such as the Heart Outcomes Prevention Evaluation Trial (HOPE) demonstrated that angiotensin converting enzyme (ACE) inhibitors such as ramipril reduce cardiovascular death, myocardial infarction, strokes and heart failure in high risk individuals, however, a significant proportion (about 20 percent) of patients are unable to tolerate an ACE-inhibitor due side effects such as coughing, hypotension or swelling.

An alternate therapy, telmisartan, which is an angiotensin II receptor blocker, proved to be at least as effective and better tolerated, offering clinicians and patients an important alternative.

“This study is of clinical importance because it demonstrates that telmisartan is an effective and safe alternative to ramipril. This means both patients and physicians have choices and can use telmisartan where appropriate with a high degree of confidence,” said Yusuf, a professor of the Michael G. DeGroote School of Medicine at McMaster. Dr. Yusuf is also vice-president of research and chief scientific officer at Hamilton Health Sciences.

Investigators from 733 centers in 40 countries collaborated in conducting the ONTARGET study, which enrolled 25,620 patients with coronary heart disease or diabetes plus additional risk factors and were over the age of 55 years of age, but did not have evidence of heart failure. Patients were randomized to receive ramipril 10-mg a day, telmisartan 18-mg a day or the combination of the two. The mean duration of follow-up of the study was 55 months.

Telmisartan and ramipril were found to be equally effective but telmisartan was better tolerated than ramipril with the chief differences being lower rates of coughing and lower rates of angioneurotic edema (a life-threatening swelling of the throat and airways). There was a small excess of minor symptoms related to hypotension such as dizziness with telmisartan.

“All people who have cardiovascular disease or diabetes with organ target damage and physicians managing these diseases should be interested in the results of this important trial,” said Dr. Gilles Dagenais, cardiologist at the Laval University Heart and Lung Institute, Quebec City, and one of the Canadian national co-ordinators of the ONTARGET trial. “If it’s possible to have access to a medication that can prevent serious cardiovascular events but with fewer side effects and better compliance than what’s currently available, it will also have a great impact on their quality of life.”

Dr. Koon Teo, professor of medicine at McMaster University and head of clinical trials in the Population Health Research Institute at Hamilton Health Sciences, said: “The ONTARGET trial is very important because it addresses the question of how we can best prevent heart attack, stroke, heart failure, cardiovascular death and other outcomes such as diabetes. These conditions affect millions of people around the world and if we can find a better treatment that improves these outcomes we’re doing a lot of good.”

Surprisingly, combination therapy did not offer any additional benefit but was associated with a higher rate of hypotension related side effects including fainting. There was also an increase in discontinuations for hyperkalemia (high potassium levels).

Veronica McGuire | EurekAlert!
Further information:
http://www.mcmaster.ca

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>